APGE
Apogee Therapeutics, Inc.
Biotechnology
Market Cap$5.60B
5Y Perf.+282.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
APGE vs RXRX vs ARQT vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
RXRX
Recursion Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.46B
5Y Perf.-76.8%
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.+89.4%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+19.2%
APGE vs RXRX vs ARQT vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | APGE | RXRX | ARQT | IMVT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $5.60B | $1.46B | $2.58B | $5.53B |
| Revenue (TTM) | $0.00 | $66M | $416M | $0.00 |
| Net Income (TTM) | $0.00 | $-560M | $-2M | $-464M |
| Gross Margin | — | -34.4% | 90.9% | — |
| Operating Margin | — | -8.8% | 0.8% | — |
| Forward P/E | — | — | 77.6x | — |
| Total Debt | $9M | $78M | $6M | $98K |
| Cash & Equiv. | $132M | $743M | $43M | $714M |
APGE vs RXRX vs ARQT vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
APGE
RXRX
ARQT
IMVT
| Stock | Jul 23 | May 26 | Return |
|---|---|---|---|
| Apogee Therapeutics… (APGE) | 100 | 382.3 | +282.3% |
| Recursion Pharmaceu… (RXRX) | 100 | 23.2 | -76.8% |
| Arcutis Biotherapeu… (ARQT) | 100 | 189.4 | +89.4% |
| Immunovant, Inc. (IMVT) | 100 | 119.2 | +19.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: APGE vs RXRX vs ARQT vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: APGE leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Arcutis Biotherapeutics, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
APGE
Apogee Therapeutics, Inc.
The Income Pick
APGE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.33
- 285.4% 10Y total return vs IMVT's 173.6%
- Lower volatility, beta 1.33, Low D/E 1.0%, current ratio 26.57x
- Beta 1.33, current ratio 26.57x
Best for: income & stability and long-term compounding
RXRX
Recursion Pharmaceuticals, Inc.
The Growth Angle
RXRX plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ARQT
Arcutis Biotherapeutics, Inc.
The Growth Play
ARQT is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 91.3%, EPS growth 88.8%, 3Y rev CAGR 367.3%
- -0.6% ROA vs IMVT's -44.1%
Best for: growth exposure
IMVT
Immunovant, Inc.
The Secondary Option
IMVT lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | APGE | 100.8% revenue growth vs IMVT's -21.3% |
| Quality / Margins | APGE | 3.2% margin vs RXRX's -8.4% |
| Stability / Safety | APGE | Beta 1.33 vs RXRX's 3.18, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | APGE | +132.2% vs RXRX's -22.0% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs IMVT's -44.1% |
APGE vs RXRX vs ARQT vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2023
Segment breakdown not available.
APGE vs RXRX vs ARQT vs IMVT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGIMVT
Who Leads Where
ARQT leads in 3 of 6 categories
APGE leads 1 • RXRX leads 0 • IMVT leads 0 • 1 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
RXRXRecursion Pharmaceuti…
0leads
APGEApogee Therapeutics, …
1leads
ARQTArcutis Biotherapeuti…
3leads
6 Total Categories
CATEGORYLEADERvs APGEvs RXRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARQT5/6
Valuation MetricsMultiples, price ratios, and targets
ARQT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
APGE6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARQT leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARQT and IMVT operate at a comparable scale, with $416M and $0 in trailing revenue. ARQT is the more profitable business, keeping -0.6% of every revenue dollar as net income compared to RXRX's -8.4%. On growth, ARQT holds the edge at +60.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | APGEApogee Therapeuti… | RXRXRecursion Pharmac… | ARQTArcutis Biotherap… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $66M | $416M | $0 |
| EBITDAEarnings before interest/tax | -$284M | -$521M | $6M | -$487M |
| Net IncomeAfter-tax profit | $0 | -$560M | -$2M | -$464M |
| Free Cash FlowCash after capex | -$233M | -$326M | $27M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | -34.4% | +90.9% | — |
| Operating MarginEBIT ÷ Revenue | — | -8.8% | +0.8% | — |
| Net MarginNet income ÷ Revenue | — | -8.4% | -0.6% | — |
| FCF MarginFCF ÷ Revenue | — | -4.9% | +6.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -56.1% | +60.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +15.6% | +56.0% | +55.0% | +19.7% |
ARQT leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
ARQT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | APGEApogee Therapeuti… | RXRXRecursion Pharmac… | ARQTArcutis Biotherap… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $5.6B | $1.5B | $2.6B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $797M | $2.5B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -19.39x | -2.27x | -158.92x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 77.64x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 19.58x | 6.87x | — |
| Price / BookPrice ÷ Book value/share | 5.49x | 1.29x | 13.87x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
ARQT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ARQT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ARQT delivers a -1.4% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-54 for RXRX. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RXRX's 0.07x. On the Piotroski fundamental quality scale (0–9), APGE scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | APGEApogee Therapeuti… | RXRXRecursion Pharmac… | ARQTArcutis Biotherap… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -31.6% | -54.3% | -1.4% | -47.1% |
| ROA (TTM)Return on assets | -30.3% | -40.6% | -0.6% | -44.1% |
| ROICReturn on invested capital | -31.3% | -95.8% | -5.2% | — |
| ROCEReturn on capital employed | -34.9% | -50.1% | -4.3% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.01x | 0.07x | 0.03x | 0.00x |
| Net DebtTotal debt minus cash | -$123M | -$665M | -$37M | -$714M |
| Cash & Equiv.Liquid assets | $132M | $743M | $43M | $714M |
| Total DebtShort + long-term debt | $9M | $78M | $6M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -336.46x | 2.08x | — |
ARQT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
APGE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in APGE five years ago would be worth $38,535 today (with dividends reinvested), compared to $1,179 for RXRX. Over the past 12 months, APGE leads with a +132.2% total return vs RXRX's -22.0%. The 3-year compound annual growth rate (CAGR) favors APGE at 56.8% vs RXRX's -16.4% — a key indicator of consistent wealth creation.
| Metric | APGEApogee Therapeuti… | RXRXRecursion Pharmac… | ARQTArcutis Biotherap… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +8.0% | -22.1% | -28.8% | +5.1% |
| 1-Year ReturnPast 12 months | +132.2% | -22.0% | +50.8% | +96.1% |
| 3-Year ReturnCumulative with dividends | +285.4% | -41.6% | +44.9% | +40.9% |
| 5-Year ReturnCumulative with dividends | +285.4% | -88.2% | -39.5% | +62.4% |
| 10-Year ReturnCumulative with dividends | +285.4% | -81.8% | -5.2% | +173.6% |
| CAGR (3Y)Annualised 3-year return | +56.8% | -16.4% | +13.2% | +12.1% |
APGE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — APGE and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
APGE is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than RXRX's 3.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs RXRX's 45.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | APGEApogee Therapeuti… | RXRXRecursion Pharmac… | ARQTArcutis Biotherap… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.33x | 3.18x | 1.48x | 1.37x |
| 52-Week HighHighest price in past year | $95.31 | $7.18 | $31.77 | $30.09 |
| 52-Week LowLowest price in past year | $34.34 | $2.80 | $12.42 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +85.8% | +45.5% | +65.0% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 49.5 | 54.3 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 865K | 12.5M | 1.3M | 1.4M |
Evenly matched — APGE and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: APGE as "Buy", RXRX as "Hold", ARQT as "Buy", IMVT as "Buy". Consensus price targets imply 236.4% upside for RXRX (target: $11) vs 33.8% for APGE (target: $109).
| Metric | APGEApogee Therapeuti… | RXRXRecursion Pharmac… | ARQTArcutis Biotherap… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $109.44 | $11.00 | $35.50 | $45.50 |
| # AnalystsCovering analysts | 10 | 10 | 12 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). APGE leads in 1 (Total Returns). 1 tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 3 of 6 categories
Loading custom metrics...
APGE vs RXRX vs ARQT vs IMVT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is APGE or RXRX or ARQT or IMVT a better buy right now?
For growth investors, Arcutis Biotherapeutics, Inc.
(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). Analysts rate Apogee Therapeutics, Inc. (APGE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — APGE or RXRX or ARQT or IMVT?
Over the past 5 years, Apogee Therapeutics, Inc.
(APGE) delivered a total return of +285. 4%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: APGE returned +285. 4% versus RXRX's -81. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — APGE or RXRX or ARQT or IMVT?
By beta (market sensitivity over 5 years), Apogee Therapeutics, Inc.
(APGE) is the lower-risk stock at 1. 33β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 138% more volatile than APGE relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 7% for Recursion Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — APGE or RXRX or ARQT or IMVT?
By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.
(ARQT) is pulling ahead at 91. 3% versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — APGE or RXRX or ARQT or IMVT?
Apogee Therapeutics, Inc.
(APGE) is the more profitable company, earning 0. 0% net margin versus -863. 4% for Recursion Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APGE leads at 0. 0% versus -867. 9% for RXRX. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is APGE or RXRX or ARQT or IMVT more undervalued right now?
Analyst consensus price targets imply the most upside for RXRX: 236.
4% to $11. 00.
07Which pays a better dividend — APGE or RXRX or ARQT or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is APGE or RXRX or ARQT or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Apogee Therapeutics, Inc.
(APGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+285. 4% 10Y return). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (APGE: +285. 4%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between APGE and RXRX and ARQT and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: APGE is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock; ARQT is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.